Ron Levy
SCIENTIFIC ADVISORY BOARD
Pharma
BeiGene
China
Biography
Professor of Medicine, Director of Lymphoma Program, Former Chief of Division of Oncology at Stanford Member of National Academy of Sciences & Institute of Medicine More than 20 years research on mAb to B cells; first to successfully treat human lymphoma with a monoclonal antibody, and went on to make important contributions to the development of rituximab (Rituxan®), for treatment of patients with resistant low-grade lymphomas
Research Interest
Pharma
